SAFETY OF INTERFERON BETA 1A FOR A SUBCUTANEOUS ADMINISTRATION IN CHILDREN AND ADOLESCENTS WITH DISSEMINATED SCLEROSIS

The onset of disseminated sclerosis occurs in childhood and juvenile age in 10% of patients. nevertheless, all immunomodulatory drugs for a treatment of this disease intended for adult population of patients, and there's an age limitation to the administration of these medications. There's only one interferon beta in group of «changing the clinical course of disseminated sclerosis medications», that was annotated to the administration in patients from 16 years. It's interferon betab1a (Rebif) for subcutaneous administration in 22 ?g and 44 ?g dosage. This drug was well known as an effective and safe medication for a long term administration for a long time in adult neurological practice. But doctors have to use interferon betab1a «off label» yet in patients younger 16 years in Russia and in other countries, comparing risk of changing the regimen of age limitation and risk of deprivation of un derbaged patient of years of qualitative life.Key words: children, disseminated sclerosis, interferon beta 1a, treatment

EARLY DIFFERENTIAL DIAGNOSTICS AND PROLONGED IMMUNOMODULATORY THERAPY OF CHRONIC INFLAMMATORY DEMYELINATING DISEASES OF CENTRAL NERVOUS SYSTEM IN CHILDREN AND ADOLESCENTS

Inflammatory demyelinating diseases in children and adolescents are sufficient problem of modern medicine. Its topicality is conditioned by as traditionally high prevalence of acute demyelinating conditions (acute disseminated encephalomyelitis) as increase of morbidity with chronic demyelinating forms of pathology (disseminated sclerosis) in children. The absence of clear diagnostic algorithm presents difficulties for the determination of tactics of treatment and prognosis on early stages of their development, e.g. at the time of maximal effectiveness of immunomodulatory medications. Besides, the list of medications for the prolonged immunomodulatory treatment of demyelinating diseases, registered in Russia, includes such drugs as interferon beta 1a for the subcutaneous injection, officially annotated for the use from 12-year old age.Key words: children, inflammatory demyelinating diseases, diagnostics, treatment.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2009;8(6):139-145)</span

EARLY DIFFERENTIAL DIAGNOSTICS AND PROLONGED IMMUNOMODULATORY THERAPY OF CHRONIC INFLAMMATORY DEMYELINATING DISEASES OF CENTRAL NERVOUS SYSTEM IN CHILDREN AND ADOLESCENTS

Inflammatory demyelinating diseases in children and adolescents are sufficient problem of modern medicine. Its topicality is conditioned by as traditionally high prevalence of acute demyelinating conditions (acute disseminated encephalomyelitis) as increase of morbidity with chronic demyelinating forms of pathology (disseminated sclerosis) in children. The absence of clear diagnostic algorithm presents difficulties for the determination of tactics of treatment and prognosis on early stages of their development, e.g. at the time of maximal effectiveness of immunomodulatory medications. Besides, the list of medications for the prolonged immunomodulatory treatment of demyelinating diseases, registered in Russia, includes such drugs as interferon beta 1a for the subcutaneous injection, officially annotated for the use from 12-year old age.Key words: children, inflammatory demyelinating diseases, diagnostics, treatment.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2009;8(6):139-145